Low Financial LeverageVery low debt-to-equity (~0.06) gives AlzeCure financial flexibility to fund R&D or absorb delays without immediate insolvency pressure. Over the next several months this structural low leverage supports pursuing partnerships or bridge financing with limited interest burden.

Asset-light Partnering ModelThe company’s R&D-focused, partner-oriented model concentrates on small-molecule CNS candidates and aims to out-license or co-develop assets. This durable strategy reduces commercialization capital needs, lets external partners fund later stages, and scales progress without heavy fixed costs.

Moderation In Cash BurnReported improvement in free cash flow versus 2024 and non-accelerating losses indicate management has begun trimming burn or sequencing spend. This moderation enhances runway predictability over coming quarters and lowers immediate financing urgency compared with prior periods.

Bears Say

No Revenue / Large LossesBeing pre-revenue with sizable TTM operating and net losses means the company relies entirely on external funding to continue development. Over 2–6 months this limits strategic flexibility, increases execution risk if raises are delayed, and heightens potential shareholder dilution.

Sustained Negative Cash FlowPersistent negative operating and free cash flow demonstrates a structural cash burn model. Continued outflows will necessitate additional financing or milestone-driven partner payments, constraining the pace of R&D and raising the probability of dilutive capital raises within months.

Financing / Dilution RiskVolatile equity and recurring deficits suggest the company will likely need recurrent external capital. With a small headcount (11 employees) and development-stage programs, limited internal resources increase dependence on market financing or partners, raising dilution and execution concentration risks.

ALZCUR FAQ

What was AlzeCure Pharma AB’s price range in the past 12 months?

AlzeCure Pharma AB lowest stock price was kr1.43 and its highest was kr4.95 in the past 12 months.

What is AlzeCure Pharma AB’s market cap?

AlzeCure Pharma AB’s market cap is kr216.61M.

When is AlzeCure Pharma AB’s upcoming earnings report date?

AlzeCure Pharma AB’s upcoming earnings report date is Feb 26, 2026 which is in 3 days.

How were AlzeCure Pharma AB’s earnings last quarter?

AlzeCure Pharma AB released its earnings results on Nov 11, 2025. The company reported -kr0.091 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.091.

Is AlzeCure Pharma AB overvalued?

According to Wall Street analysts AlzeCure Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does AlzeCure Pharma AB pay dividends?

AlzeCure Pharma AB does not currently pay dividends.

What is AlzeCure Pharma AB’s EPS estimate?

AlzeCure Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AlzeCure Pharma AB have?

AlzeCure Pharma AB has 114,914,450 shares outstanding.

What happened to AlzeCure Pharma AB’s price movement after its last earnings report?

AlzeCure Pharma AB reported an EPS of -kr0.091 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.366%.

Which hedge fund is a major shareholder of AlzeCure Pharma AB?

Currently, no hedge funds are holding shares in SE:ALZCUR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

AlzeCure Pharma AB

AlzeCure Pharma AB (ALZCUR) is a Swedish pharmaceutical company that focuses on developing innovative therapies for neurodegenerative diseases, with a particular emphasis on Alzheimer's disease and pain management. The company operates in the biotechnology sector, leveraging its expertise in neuroscience to advance its pipeline of drug candidates. AlzeCure's core products include a range of proprietary small molecule drugs that target key pathways involved in neurodegeneration.